Name: Anti-Ad Fiber Knob x Anti-EPCAM Bispecific Antibody (IgG-IgG)
SKU: BSIG-004
Rating: 5 (1 reviews)

Anti-Ad fiber knob x Anti-EPCAM Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-Ad fiber knob and anti-EPCAM parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can retarget of adenoviral vectors to tumour cells. It can be used in cancer gene therapy to transfer a therapeutic gene into tumour cells aiming at selective and efficient cell killing.

Datasheet INQUIRY

Specifications

Targets

Ad Fiber Knob & EPCAM

Type

IgG-IgG

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Breast cancer; Ovary cancer; Colon cancer; Lung cancer

Targets

Target 1

Ad Fiber Knob

Alternative Names

Ad fiber knob; Adenovirus fiber knob; adenovirus fiber protein; knob domain of Ad fiber

Target 2

EPCAM

Gene ID

4072

UniProt ID

P16422

Alternative Names

EPCAM; epithelial cell adhesion molecule; ESA; KSA; M4S1; MK-1; DIAR5; EGP-2; EGP40; KS1/4; MIC18; TROP1; EGP314; HNPCC8; TACSTD1; epithelial glycoprotein 314; human epithelial glycoprotein-2; cell surface glycoprotein Trop-1; adenocarcinoma-associated antigen; tumor-associated calcium signal transducer 1; major gastrointestinal tumor-associated protein GA733-2; membrane component, chromosome 4, surface marker (35kD glycoprotein)

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Related products of "Ad Fiber Knob & EPCAM"

See other bsAb targets related to "Ad Fiber Knob"

See other bsAb targets related to "EPCAM"

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-Ad Fiber Knob x Anti-EPCAM Bispecific Antibody (IgG-IgG) (BSIG-004). Click the button below to contact us or submit your feedback about this product.

Anti-Ad Fiber Knob x Anti-EPCAM Bispecific Antibody (IgG-IgG) (CAT#: BSIG-004)

Specifications

Targets

Customer Reviews and Q&As